Dyne Therapeutics launches with $50 million for oligonucleotide muscle delivery
Tuesday, May 28, 2019 - 21:10
in Biology & Nature
The startup, founded by Atlas Venture, is developing antibody-oligonucleotide conjugates for genetic muscle diseases